

November 7, 2025

Trade name: Noevir Holdings Co., Ltd.
Listing: Tokyo Stock Exchange, Prime Market (Securities Code: 4928)
URL: <https://www.noevirholdings.co.jp/english/>
Representative: Takashi Okura, President and CEO
Contact: Tatsuyuki Tanaka, Executive Officer, Corporate and Legal Affairs
Tel. +81-3-6731-2327

Changes among Representative Directors and Directors of Subsidiary Companies

The company decided to make the following change to the representative director and director of 2 Subsidiary Companies.

This matter is scheduled to be officially decided at the Annual General Meetings of Shareholders and the Board of Directors' meetings of each subsidiary company, scheduled to be held on November 27, 2025.

Noevir Co., Ltd. (As of November 27, 2025)

Representative Director

	New title	Former title
Yasuo Kaiden	Chairman	Chairman and Representative Director

The above change is made due to the reorganization of the management structure.

Directors

	New title	Former title
Yasuo Kaiden	Chairman	Chairman and Representative Director
Akihiro Keyari	President and CEO	President and CEO
Masanao Nakao	Vice President and Representative Director	Vice President and Representative Director
Tetsuo Shoji	Vice President and Representative Director	Vice President and Representative Director
Taizo Seki	Director CTO*1 Plant Material, New Business, Satellite Research Center*2 & Industry-Academia Collaboration	Director Noevir Group Research Laboratory
Motona Sugimasa	Director East Asia Business Development	Director Overseas Business Development
Naoya Sasaki	Director Human Resources and Corporate Affairs	Director Human Resources and Corporate Affairs
Seiji Kurita	Director Intellectual Property and Quality Assurance & Pharmaceuticals and Health foods Product Development	Executive Officer Noevir Group Research Laboratory, Pharmaceuticals and Health foods Product Development & Intellectual Property and Regulatory Affairs

	New title	Former title
Chisato Takayanagi	Director Domestic Business Development	Executive Officer Domestic Business Development
Ryo Minato	Director North America Business Development	Executive Officer Noevir U.S.A., Inc.

Notes *1: CTO stands for Chief Technology Officer.

*2: The term “Satellite Research Center” refers to Hokkaido Shokanbetsu Mountain Pilot Farm, Suzuka Alpine Plants Research Center, and Minami Daito Island Marine Research Center.

TOKIWA Pharmaceutical Co., Ltd. (As of November 27, 2025)

Representative Director

	New title	Former title
Masataka Nakano	Chairman	Chairman and Representative Director

The above change is made due to the reorganization of the management structure.

Directors

	New title	Former title
Masataka Nakano	Chairman	Chairman and Representative Director
Kouzou Matsushita	President and CEO	President and CEO
Masao Tainaka	Vice President and Representative Director	Vice President and Representative Director
Kazuki Nakata	Director Human Resources and Corporate Affairs	Director Human Resources and Corporate Affairs
Hideyuki Kanda	Director Pharmaceuticals and Health foods Division	Director Beauty & Healthcare
Ryosuke Arai	Director NOV Division	Director NOV Division
Tatsuya Kusaka	Director SANA Division	Director SANA Division & Product Planning
Kanade Tajima	Director Product Planning	Executive Officer Product Planning
Hiroyuki Nakajima	Director (TOKIWA Medical Service Co., Ltd. President and CEO)	TOKIWA Medical Service Co., Ltd. Director

The concurrent position of Hiroyuki Nakajima at TOKIWA Medical Service Co., Ltd. is scheduled to be officially decided at the Annual General Meeting of Shareholders and the Board of Directors’ meeting to be held on November 28, 2025.